| Description | BMS493 is an inverse agonist of the pan-retinoic acid receptor (RAR) that inhibits retinoic acid-induced differentiation, enhances the interaction of nuclear co-inhibitors with RARs, attenuates RA signaling, potentiates TPP-induced toxicity, and inhibits the increase in phospholipase A2 activity. |
| In vitro | BMS 493 (100 nM；6 天)处理的细胞显示可用于移植的 ALDHhi 细胞数量比未处理对照组增加了两倍。新扩增的 ALDHhi 细胞显示 CD34 和 CD133 阳性细胞数量增加，同时 CD38 表达减少[1]. |
| In vivo | 与新鲜分离的 ALDHhi 细胞相比，经过 6 天的扩增，无论是否添加 BMS 493，所产生的后代都无法在转移到 STZ 处理的 NOD/SCID 小鼠后降低高血糖[1]。 |
| Synonyms | BMS-493 |
| molecular weight | 404.5 |
| Molecular formula | C29H24O2 |
| CAS | 215030-90-3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 30 mg/mL (74.16 mM), Sonication is recommended. |
| References | 1. Elgamal RM, et al. BMS 493 Modulates Retinoic Acid-Induced Differentiation During Expansion of Human Hematopoietic Progenitor Cells for Islet Regeneration. Stem Cells Dev. 2018 Aug 1;27(15):1062-1075. 2. Yu Z, et al. Apoptosis induced by atRA in MEPM cells is mediated through activation of caspase and RAR. Toxicol Sci. 2006 Feb;89(2):504-9. |